Synthorx to Present at Upcoming Investor Conferences
November 13, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx Reports Third Quarter Financial Results
November 05, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting
November 05, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 29, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress
September 23, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx to Present at the 2019 World Congress of Inflammation
September 09, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference
August 29, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx Reports Second Quarter Financial Results
August 01, 2019 16:05 ET
|
Synthorx, Inc.
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (Nasdaq: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today...
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
July 24, 2019 08:00 ET
|
Synthorx, Inc.
SAN DIEGO, July 24, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, announced...
Synthorx to Present at Jefferies 2019 Healthcare Conference
May 29, 2019 16:10 ET
|
Synthorx, Inc.
SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ: THOR), a biotechnology company using a first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop...